Tenaya Therapeutics (TNYA) Accounts Payables (2020 - 2026)

Tenaya Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 62.2% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 62.2% YoY), while the FY2025 annual figure was $3.6 million, down 30.63% from the prior year.
• Accounts Payables was $1.9 million for Q1 2026 at Tenaya Therapeutics, down from $3.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $9.6 million in Q4 2022 to a low of $1.9 million in Q1 2026.
• Historically, Accounts Payables has averaged $5.6 million across 5 years, with a median of $5.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Accounts Payables surged 58.67% in 2023, then sank 62.2% in 2026.
• A 5-year view of Accounts Payables shows it stood at $9.6 million in 2022, then plunged by 41.22% to $5.6 million in 2023, then retreated by 8.31% to $5.2 million in 2024, then plunged by 30.63% to $3.6 million in 2025, then plunged by 46.55% to $1.9 million in 2026.
• The last three Accounts Payables figures came in at $1.9 million (Q1 2026), $3.6 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.